Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hypofractionated Radiotherapy and AI Chemotherapy for Extremity Soft Tissue Sarcoma
NCT06593899Phase 2Recruiting
- Sponsor
- Fujian Medical University Union Hospital
- Start
- May 2024
- Primary completion
- Dec 2025
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of doxorubicin and ifosfamide in soft tissue sarcoma (STS), sponsored by Fujian Medical University Union Hospital. Primary endpoint: Proportion of EORTC-STBSG classifications A-C. Started May 2024; status: recruiting.
02
Drugs
doxorubicinifosfamide
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT06593899.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06593899.